Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes ...Middle East

– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in...

Read More Details
Finally We wish PressBee provided you with enough information of ( Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes )

Also on site :

• 'He knows where to find me,' Newsom responds to Trump administration arrest threat
• Two people killed by falling trees and thousands without power after storms sweep southern states
• Brynn Whitfield Announces Exit From 'RHONY' After Two Seasons